

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this Application:

Listing of Claims:

1-32 (Canceled).

33. (Currently amended) A method for treatment or prevention of a vascular disease or states of tissue hypoperfusion, said disease or states of tissue hypoperfusion with hypoxic or ischemic consequences leading to hypoxia or ischemia in a patient, with the proviso that said method does not pertain to coronary ischemia, the method comprising the following steps:

~~selecting a substance from the group consisting of human apo-lactoferrin, human lactoferricin, peptides derivable from human lactoferrin, natural metabolites of human lactoferrin, and functionally equivalent analogues of human apo-lactoferrin;~~

~~— determining a therapeutically effective amount of the selected substance;~~

~~administering the—a therapeutically effective amount of human apo-lactoferrin the selected substance to the patient~~

~~whereby the method is used as an alternative to bypass surgery or any therapeutic angiogenesis options.~~

34. (Currently amended) The method as recited in claim 33 whereby the method is used for treating impending stroke, manifested stroke, ischemic heart disease such as angina pectoris or impending or manifested myocardial infarction, and peripheral artery occlusive disease with or without impending gangrene.

35. (Previously presented) The method as recited in claim 33 whereby the method is used for treating vascular disease, state of tissue hypoperfusion, or state of depressed VEGF induced angiogenesis associated with peptic ulcer, leg ulcer or local or generalised hair loss.

36. (Previously presented) The method as recited in claim 33 wherein said substance is administered orally.

37. (Previously presented) The method as recited in claim 33 wherein said substance is administered parenterally.

38. (Previously presented) The method as recited in claim 33 wherein said substance is administered locally.

39. (Previously presented) The method as recited in claim 33 wherein said substance is administered by inhalation.

40. (Currently amended) A method for treatment or prevention of a vascular disease or states of tissue hypoperfusion, said disease or states of tissue hypoperfusion with hypoxic or ischemic consequences leading to hypoxia or ischemia in a patient, with the proviso that said method does not pertain to coronary ischemia, the method comprising the following steps:

selecting a substance from the group consisting of human apo-lactoferrin, human lactoferricin, and a peptide from the group consisting of peptides derivable from human lactoferrin having an amino acid sequence constituted of amino acids 12-40 of human lactoferrin counted from the N-terminal end or a smaller fragment thereof which is at least 7 amino acids long, and optionally wherein said peptide is modified such that C-20 is replaced by A, Q-22 is replaced by K, and N-26 is replaced by D, wherein said peptide is active in stimulating VEGF-mediated angiogenesis;

determining a therapeutically effective amount of the selected substance; and

administering the therapeutically effective amount of the selected substance to the patient

~~whereby the method is used as an alternative to bypass surgery or any therapeutic angiogenesis options.~~

41. (Canceled).

42. (Currently amended) The method as recited in claim 40 wherein the peptide comprises a peptide formed of the sequences constituted of amino acids 16-40 ~~and or~~ amino acids 18-40 from the N-terminal end of human lactoferrin, or ~~a~~the modified version thereof.

43. (Previously presented) The method as recited in claim 40 wherein the peptide comprises a peptide essentially corresponding to residues 18-31 of human lactoferrin wherein C-20 is replaced by A, Q-22 is replaced by K, and N-26 is replaced by D.

44. (Currently amended) The method as recited in claim 40 wherein the peptide comprises a peptide formed of the amino acids in positions 12-31, counted from the N-terminal end, in the sequence constituting human lactoferrin, or ~~a~~the modification thereof, or ~~a~~the fragment thereof consisting of at least 7 amino acids.

45. (Currently amended) The method as recited in claim 40 wherein the peptide is a peptide consisting of 11-17 amino acids corresponding to the sequences that begin with one of the amino acids in positions 15-21 and end with the amino acid in position 31, counted from the N-terminal end, in the sequence constituting human lactoferrin, or ~~a~~the modification thereof.

46. (Currently amended) The method as recited in claim 40 wherein the peptide is a peptide consisting of 12 amino acids having based on the sequence consisting of the amino acids in positions 20-31 in human lactoferrin, counted from the N-terminal end.

47. (Currently amended) The method as recited in claim 40 whereby the method is used for treating impending stroke, manifested stroke, ~~ischemic heart disease such as angina pectoris or~~ ~~impending or manifested myocardial infarction,~~ and peripheral artery occlusive disease ~~with or~~ ~~without impending gangrene.~~

48. (Previously presented) The method as recited in claim 40 whereby the method is used for treating vascular disease, state of tissue hypoperfusion, or state of depressed VEGF induced angiogenesis associated with peptic ulcer, leg ulcer or local or generalised hair loss.

49. (Previously presented) The method as recited in claim 40 wherein said substance is administered orally.

50. (Previously presented) The method as recited in claim 40 wherein said substance is administered parenterally.

51. (Previously presented) The method as recited in claim 40 wherein said substance is administered locally.

52. (Previously presented) The method as recited in claim 40 wherein said substance is administered by inhalation.

53. (New) The method as recited in claim 34 wherein the treatment is for peripheral artery occlusive disease wherein conventional treatment is surgery or therapeutic angiogenesis and said method is used as an alternative to said conventional treatment.